Geneoscopy

Company profile

About Geneoscopy

Geneoscopy is a precision medicine company focused on transforming gastrointestinal health through innovative molecular diagnostic tests. The company has developed a proprietary stool-derived eukaryotic RNA (seRNA) technology platform that enables noninvasive screening, detection, and monitoring of gastrointestinal diseases. Geneoscopy's flagship product, ColoSense, is the first FDA-approved RNA-based stool test for colorectal cancer screening in adults aged 45 and older. The company's mission is to empower patients and healthcare providers with molecular-based tests that help prevent, detect, and monitor disease. By offering a convenient, at-home collection method, Geneoscopy addresses the significant gap in colorectal cancer screening rates, where over 40% of eligible patients fail to get screened due to the inconvenience and invasive nature of colonoscopies. Beyond colorectal cancer, Geneoscopy is advancing applications of its stool RNA technology to monitor disease activity and predict therapeutic response in inflammatory bowel disease. The company partners with biopharma organizations and research institutions to develop companion diagnostics and clinical trial tools. Geneoscopy's platform-agnostic RNA extraction technology can be evaluated using next-generation sequencing, ddPCR, qPCR, molecular barcoding, or microarray technology, providing comprehensive insights into the stool-derived transcriptome for various gastrointestinal disease indications.

Company description · Geneoscopy official website